Online citations, reference lists, and bibliographies.
← Back to Search

Secondary Analyses Of The Efficacy Of Two Acellular Pertussis Vaccines Evaluated In A Swedish Phase III Trial.

J. Storsaeter, H. Hallander, C. Farrington, Patrick W. Olin, R. Möllby, E. Miller
Published 1990 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
A placebo-controlled efficacy trial of two acellular pertussis vaccines carried out in Sweden in 1986-87 used culture confirmation as the principal case definition. However, the sensitivity of pertussis culture is low, and secondary analyses using more sensitive serological diagnostic criteria have therefore been carried out. These analyses confirm that vaccination with pertussis toxoid alone does protect against typical whooping cough with laboratory confirmation, but show that it does not protect against infection or colonization. There is evidence that the addition of filamentous haemagglutinin provides some protection against infection. Bacterial isolation rates were lower in vaccinated than unvaccinated children with serologically confirmed pertussis and increased with disease severity.
This paper references



This paper is referenced by
10.1006/BIOL.1999.0184
Overview of recent clinical trials of acellular pertussis vaccines.
E. Miller (1999)
10.1016/S1387-2656(08)70018-8
Novel molecular biology approaches to acellular vaccines.
R. Rappuoli (1996)
10.1086/426454
The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.
J. Robbins (2005)
Mifler Acellular pertussis vaccines
()
, Senegal Hemagglutinin in Diagnosis of Pertussis in Pertussis Toxin and Filamentous Enzyme-Linked Immunosorbent Assay for Evaluation of an Immunoglobulin
F. Simondon (1997)
Epidemiological, virological, and clinical features of an epidemic of hand, foot, and mouth disease in England and Wales.
J. Bendig (1996)
10.3109/00365549509019021
Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis.
J. Isacson (1995)
10.1542/PEDS.108.6.E115
Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.
J. Taranger (2001)
10.1016/J.FEMSLE.2004.09.009
Antibodies produced against a fragment of filamentous haemagglutinin (FHA) of Bordetella pertussis are able to inhibit hemagglutination induced by the whole adhesin.
D. Colombi (2004)
Ventajas de la vacuna DTPa sobre la DTPw
C. R. G. D. Liria (2003)
10.1542/peds.102.4.909
The Effect of Investigator Compliance (Observer Bias) on Calculated Efficacy in a Pertussis Vaccine Trial
J. Cherry (1998)
10.1016/S0022-3476(05)80227-6
Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children.
A. Podda (1992)
10.1086/322618
A trial of acellular pertussis vaccine in hospital workers during the Cincinnati pertussis epidemic of 1993.
C. Christie (2001)
10.1016/S0022-3476(05)83181-6
Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
A. Podda (1994)
10.1016/0264-410X(91)90290-M
Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.
A. Podda (1991)
10.1086/515055
A commentary on the pathogenesis of pertussis.
E. Hewlett (1999)
10.1097/00006454-199704001-00002
Pertussis: current concepts of pathogenesis and prevention.
E. Hewlett (1997)
10.1097/00006454-199711000-00007
Efficacy of a two-component acellular pertussis vaccine in infants.
J. Liese (1997)
Investigation of pertussis toxin A- and B-subunit activities in acellular vaccines by enzymatic and carbohydrate-binding assays
Sheena Robin Gomez (2007)
10.1542/peds.2011-2594
Why Do Pertussis Vaccines Fail?
J. Cherry (2012)
10.2165/00063030-199912030-00002
Developing Better Paediatric Vaccines
S. Halperin (2012)
10.1016/S0171-2985(11)80477-8
Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin.
R. Rappuoli (1992)
Monocomponent Pertussis Toxoid Vaccine Immunologic and Epidemiologic Experience of Vaccination With a
R. Schneerson (2013)
10.1128/IAI.61.2.486-490.1993
Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species.
N. Khelef (1993)
10.1080/21645515.2018.1480298
Prevention of pertussis: An unresolved problem
S. Esposito (2018)
10.1637/8471-092308-Reg.1
Protection Against Fowl Cholera Conferred by Vaccination with Recombinant Pasteurella multocida Filamentous Hemagglutinin Peptides
F. Tatum (2009)
10.1586/erv.09.88
Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience
H. Hallander (2009)
10.1093/INFDIS/168.1.15
Acellular pertussis vaccines--a solution to the pertussis problem?
K. Edwards (1993)
10.1002/14651858.CD001478.pub6
Acellular vaccines for preventing whooping cough in children.
L. Zhang (2014)
10.1016/J.VACCINE.2003.09.039
A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety.
E. Mallet (2004)
10.1007/s15010-016-0943-6
Parents as source of pertussis transmission in hospitalized young infants
G. Fedele (2016)
10.1542/PEDS.104.6.1381
The science and fiction of pertussis vaccines.
J. Cherry (1999)
See more
Semantic Scholar Logo Some data provided by SemanticScholar